Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The effects of combination anti-angiogenesis therapy (marimastat, captopril and fragmin) on plasma levels of coagulation initiator tissue factor (TF), platelet marker soluble P-selectin and angiogenic vascular endothelial growth factor (VEGF) were tested in 25 patients with advanced cancer. They had higher soluble P-selectin (P<0.001) and TF (P<0.001), but not VEGF (P=0.066) than 25 age and sex-matched controls. VEGF and TF correlated significantly (r=0.8, P<0.001) in cancer patients. Soluble P-selectin, TF and VEGF did not change at 4- and 8-weeks whilst on treatment. We provide further evidence linking coagulation and angiogenesis but combination anti-angiogenesis therapy does not influence plasma soluble P-selectin, TF or VEGF.

Original publication

DOI

10.1016/j.canlet.2004.09.036

Type

Journal article

Journal

Cancer lett

Publication Date

10/03/2005

Volume

219

Pages

163 - 167

Keywords

Adult, Aged, Angiogenesis Inhibitors, Anticoagulants, Captopril, Dalteparin, Female, Humans, Hydroxamic Acids, Male, Middle Aged, Neoplasms, Neovascularization, Pathologic, P-Selectin, Platelet Activation, Thromboplastin, Vascular Endothelial Growth Factor A